Gliomatosis cerebri MRI: Difference between revisions

	Gliomatosis cerebri Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gliomatosis cerebri from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gliomatosis cerebri MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gliomatosis cerebri MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gliomatosis cerebri MRI
CDC on Gliomatosis cerebri MRI
Gliomatosis cerebri MRI in the news
Blogs on Gliomatosis cerebri MRI
Directions to Hospitals Treating Gliomatosis cerebri
Risk calculators and risk factors for Gliomatosis cerebri MRI

Revision as of 20:32, 24 September 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Brain MRI is helpful in the diagnosis of gliomatosis cerebri. On brain MRI, gliomatosis cerebri is characterized by:^[1]


MRI component	Findings

T1	Iso to hypointense to grey matter
T2	Hyperintense to grey matter
T1C+	No or minimal enhancement
DWI	No restriction
MR spectroscopy	Elevated choline/creatine and choline/NAA ratios Marked elevation of myo-inositol
MR perfusion	Low/normal rCBV Correlates with no vascular hyperplasia

↑ Radiographic features of gliomatosis cerebri. Dr Henry Knipe and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/gliomatosis-cerebri

@@ Line 19: / Line 19: @@
 T1
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:iso to hypointense to grey matter
+*Iso to hypointense to grey matter
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
 T2
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:hyperintense to grey matter
+*Hyperintense to grey matter
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
 T1C+
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:No or minimal enhancement
+*No or minimal enhancement
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
 DWI
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:No restriction
+*No restriction
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
 MR spectroscopy
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:Elevated [[choline]]/[[creatine]] and [[choline]]/NAA ratios
+*Elevated [[choline]]/[[creatine]] and [[choline]]/NAA ratios
-:Marked elevation of myo-inositol
+*Marked elevation of myo-inositol
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
 MR perfusion
 | style="padding: 5px 5px; background: #F5F5F5;" |
-:Low/normal rCBV
+*Low/normal rCBV
-:*Correlates with no vascular hyperplasia
+*Correlates with no vascular hyperplasia
 |}